News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

7TM Pharma Completes Positron Emission Tomography Preclinical Research Program To Successfully Demonstrate Peripheral Restriction Of Its CB1 Receptor Antagonist TM38837



7/12/2010 1:59:53 PM

Hoersholm – July 12th, 2010: 7TM Pharma today announced positive preclinical Positron Emission Tomography (PET) data in non human primates with their proprietary drug candidate TM38837, which was discovered at 7TM Pharma and is being developed for treatment of obesity, type 2 diabetes and related metabolic disorders. In line with a full range of other experiments, the data clearly demonstrate the principle feature of this first in class compound, namely that it is peripherally restricted. A direct comparison between TM38837 and rimonabant, a brain penetrant CB1 receptor antagonist, importantly exhibited a clear difference between their propensities to cross the blood brain barrier in favor of TM38837.

TM38837 is a first in class, peripheral CB1 receptor antagonist. It was designed to avoid the risk of psychiatric side effects through its restriction to peripherally located CB1 receptors in the body. This approach is in contrast to the first generation CB1 receptor antagonists, which also targeted CB1 receptors within the central nervous system. Although clinically effective, these had an unfavorable psychiatric side effect profile including depression and anxiety.

Christian E. Elling, Vice President, commented: “Our first in class peripheral CB1 antagonist TM38837 continues to return very promising distribution data, validating that it is restricted to CB1 receptors outside the CNS, at what have been demonstrated to be relevant efficacious doses in various models of obesity and type 2 diabetes. These results have encouraged us to move TM38837 forward in clinical development. We intend to partner the program during clinical development to further accelerate the program to the benefit of the growing number of obese and diabetic patients requiring safe and effective medicines”.

7TM Pharma Contact person: Christian E. Elling, VP Tel: +45 3925 7777 Email: cee@7tm.com July 12th, 2010

Fremtidsvej 3 DK-2970 Hørsholm Denmark Tel. +45 39 25 77 77 Fax. +45 39 25 77 76

About TM38837

TM38837 is a small molecule CB1 receptor antagonist discovered and developed by 7TM Pharma. Beyond a clinical development enabling program, TM38837 has completed a broad spectrum of in vivo studies supporting the thesis of peripheral restriction whilst maintaining efficacy in a range of models of obesity and type 2 diabetes.

About obesity and related metabolic diseases Obesity and related metabolic diseases are considered to be a major health problem and challenge to the industrialized world. Obesity significantly increases the risk of diseases such as cardiovascular diseases and type 2 diabetes and involves significant costs to healthcare budgets. According to the WHO, there are more than 400 million clinically obese people worldwide – i.e. people with a BMI of more than 30 kg/m2 – and the number is growing fast. In spite of this, there are only few currently available therapies for obesity. These drugs have a limited effect and significant side effects and there is consequently a large, unmet need for new and better therapies.

About 7TM Pharma

7TM Pharma is a biotech company focusing on the clinical development of drugs with a primary therapeutic focus on obesity, gastrointestinal diseases and, in collaboration with its partner Ortho- McNeil-Janssen Pharmaceuticals (a Johnson and Johnson company) inflammation. 7TM Pharma’s approach is to progress their product candidates into the early clinical development and secure licensing partners for the advanced develoment and for commercialization.

7TM’s investors include Alta Partners, GLSV, GIMV, Index Ventures, J&J Development Corporation, LD Pensions, Novo A/S, Scottish Widows, Sofinnova and SR One. For more information on 7TM Pharma, please visit www.7tm.com.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES